Search

Displaying results 4271 - 4280 of 10000 in total
  1. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  2. Drug

    Denatonium

    go.drugbank.com/drugs/DB18588
    Investigational

    Synonyms: Benzenemethanaminium, n-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)-n,n-diethylCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

  4. Drug

    Alvespimycin

    go.drugbank.com/drugs/DB12442
    Investigational

    Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility

  5. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. … It is developed by MedImmune for the treatment of Allergic Rhinitis.

  6. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.

  7. Drug

    4-O-Demethylpenclomedine

    go.drugbank.com/drugs/DB06331
    Experimental

  8. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase

  9. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  10. Drug

    Carbinoxamine

    go.drugbank.com/drugs/DB00748
    Approved

    The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many … unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under